Experienced in Acid Sphingomyelinase Deficiency (ASMD)

Mireia D. Del Toro-Riera

Barcelona, CT, ES 
Experienced in Acid Sphingomyelinase Deficiency (ASMD)
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Mireia Del Toro-Riera practices in Barcelona, Spain. Ms. Del Toro-Riera is rated as an Experienced expert by MediFind in the treatment of Acid Sphingomyelinase Deficiency (ASMD). Her top areas of expertise are Mucopolysaccharidosis Type 3A (MPS IIIA, Sanfilippo Syndrome A), Niemann-Pick Disease, Propionic Acidemia, and Non-Langerhans-Cell Histiocytosis.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 2 clinical trials in the study of Acid Sphingomyelinase Deficiency (ASMD).

Gender
Female

Locations

Barcelona, CT 08035, Spain
Other Locations
Sevilla, AN, Spain
Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: SHP611
Study Phase: Phase 2
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 2/Phase 3
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
Enrollment Status: Completed
Publish Date: May 18, 2017
View 2 Less Clinical Trials

58 Total Publications

Non-neurological, non skeletal outcomes after hematopoietic stem and progenitor cell-gene therapy -OTL-203- for Hurler syndrome.
Non-neurological, non skeletal outcomes after hematopoietic stem and progenitor cell-gene therapy -OTL-203- for Hurler syndrome.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Del Toro-Riera's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 34 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile